{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:53:26Z","timestamp":1790477606200,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Italian Institute for Genomic Medicine Institutional"},{"name":"Gilead Fellowship program 2018"},{"name":"Ministry of Education University and Research-MIUR, PRIN","award":["2017CBNCYT"],"award-info":[{"award-number":["2017CBNCYT"]}]},{"name":"Progetto strategico di Eccellenza Dipartimentale","award":["#D15D18000410001"],"award-info":[{"award-number":["#D15D18000410001"]}]},{"name":"ITN INTEGRATA","award":["813284"],"award-info":[{"award-number":["813284"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cell &amp; Developmental Biology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.semcdb.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T01:45:12Z","timestamp":1557798312000},"page":"192-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT)"],"prefix":"10.1016","volume":"98","author":[{"given":"Valentina","family":"Audrito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Manag\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.semcdb.2019.05.001_bib0005","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6892","key":"10.1016\/j.semcdb.2019.05.001_bib0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.semcdb.2019.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"279","key":"10.1016\/j.semcdb.2019.05.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0030","first-page":"522","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, the Lancet","volume":"16","author":"Eggermont","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fimmu.2018.00403","article-title":"Corrigendum: association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: an italian melanoma intergroup study","volume":"9","author":"Queirolo","year":"2018","journal-title":"Front. Immunol."},{"issue":"6029","key":"10.1016\/j.semcdb.2019.05.001_bib0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"5899","key":"10.1016\/j.semcdb.2019.05.001_bib0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"19","key":"10.1016\/j.semcdb.2019.05.001_bib0055","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0060","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdv255","article-title":"The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600","volume":"26","author":"Massi","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.semcdb.2019.05.001_bib0070","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.semcdb.2019.05.001_bib0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.semcdb.2019.05.001_bib0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5930","key":"10.1016\/j.semcdb.2019.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.semcdb.2019.05.001_bib0105","doi-asserted-by":"crossref","first-page":"62726","DOI":"10.18632\/oncotarget.10911","article-title":"Oncogenic regulation of tumor metabolic reprogramming","volume":"7","author":"Tarrado-Castellarnau","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2014.12.007","article-title":"Molecular drivers of cellular metabolic reprogramming in melanoma","author":"Abildgaard","year":"2015","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/onc.2016.198","article-title":"Metabolic rewiring in melanoma","volume":"36","author":"Ratnikov","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0120","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-13-0898","article-title":"Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation","volume":"20","author":"Haq","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0125","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/cr.2017.155","article-title":"Mitochondrial metabolism and cancer","volume":"28","author":"Porporato","year":"2018","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0135","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","article-title":"Mitochondria and Cancer","volume":"166","author":"Vyas","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molmed.2017.11.005","article-title":"Metabolic control of CD8(+) t cell fate decisions and antitumor immunity","volume":"24","author":"Zhang","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"O\u2019Neill","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0150","article-title":"Altered cancer metabolism in mechanisms of immunotherapy resistance","author":"Ramapriyan","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd4145","article-title":"Metabolic targets for cancer therapy","volume":"12","author":"Galluzzi","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fonc.2017.00068","article-title":"Metabolic cooperation and competition in the tumor microenvironment: implications for therapy","volume":"7","author":"Gupta","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2016.02.009","article-title":"Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma","volume":"107","author":"Smith","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.canlet.2018.11.018","article-title":"Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma","volume":"442","author":"Brummer","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0175","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.2741\/3143","article-title":"Enzymology of mammalian NAD metabolism in health and disease","volume":"13","author":"Magni","year":"2008","journal-title":"Front. Biosci."},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/er.2009-0026","article-title":"The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways","volume":"31","author":"Houtkooper","year":"2010","journal-title":"Endocr. Rev."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0185","first-page":"741","article-title":"The NAD metabolome--a key determinant of cancer cell biology, Nature reviews","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0190","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cmet.2018.02.011","article-title":"Therapeutic potential of NAD-Boosting molecules: the in vivo evidence","volume":"27","author":"Rajman","year":"2018","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0195","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0200","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2018.01.001","article-title":"The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: diagnostic and therapeutic perspectives and challenges","volume":"82","author":"Dalamaga","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer","volume":"151","author":"Sampath","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"7130","key":"10.1016\/j.semcdb.2019.05.001_bib0210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature05660","article-title":"Melanocyte biology and skin pigmentation","volume":"445","author":"Lin","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","article-title":"Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis","volume":"4","author":"Parmenter","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0220","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbagen.2018.01.018","article-title":"Melanoma metabolism contributes to the cellular responses to MAPK\/ERK pathway inhibitors","volume":"1862","author":"Marchetti","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0225","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0230","doi-asserted-by":"crossref","first-page":"584","DOI":"10.18632\/oncotarget.965","article-title":"Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene","volume":"4","author":"Hall","year":"2013","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.semcdb.2019.05.001_bib0235","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1200\/JCO.2011.39.1938","article-title":"Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma","volume":"30","author":"McArthur","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.semcdb.2019.05.001_bib0245","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-06-3312","article-title":"Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma","volume":"67","author":"Kumar","year":"2007","journal-title":"Cancer Res."},{"issue":"43","key":"10.1016\/j.semcdb.2019.05.001_bib0250","doi-asserted-by":"crossref","first-page":"E924","DOI":"10.1073\/pnas.1106351108","article-title":"Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF","volume":"108","author":"Feige","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7452","key":"10.1016\/j.semcdb.2019.05.001_bib0255","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature12154","article-title":"A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence","volume":"498","author":"Kaplon","year":"2013","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.semcdb.2019.05.001_bib0260","doi-asserted-by":"crossref","first-page":"39473","DOI":"10.18632\/oncotarget.7790","article-title":"Mitochondrial oxidative phosphorylation controls cancer cell\u2019s life and death decisions upon exposure to MAPK inhibitors","volume":"7","author":"Corazao-Rozas","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0265","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1172\/JCI82661","article-title":"Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors","volume":"126","author":"Zhang","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.abb.2014.04.007","article-title":"Updates of reactive oxygen species in melanoma etiology and progression","volume":"563","author":"Liu-Smith","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0275","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc3803","article-title":"Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles\u2019 heel?","volume":"14","author":"Sabharwal","year":"2014","journal-title":"Nat. Rev."},{"issue":"8","key":"10.1016\/j.semcdb.2019.05.001_bib0280","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-08-0298","article-title":"Elesclomol induces cancer cell apoptosis through oxidative stress","volume":"7","author":"Kirshner","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"28","key":"10.1016\/j.semcdb.2019.05.001_bib0285","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1074\/jbc.M117.786442","article-title":"Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition","volume":"292","author":"Trotta","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"6 Pt B","key":"10.1016\/j.semcdb.2019.05.001_bib0290","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.bbamcr.2015.11.032","article-title":"Pharmacological targeting of ion channels for cancer therapy: in vivo evidences","volume":"1863","author":"Leanza","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0295","doi-asserted-by":"crossref","first-page":"e2594","DOI":"10.1038\/cddis.2017.6","article-title":"Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells","volume":"8","author":"Bauer","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0300","doi-asserted-by":"crossref","DOI":"10.1111\/exd.12718","article-title":"Combining BRAF inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma","author":"Livingstone","year":"2015","journal-title":"Exp. Dermatol."},{"issue":"45","key":"10.1016\/j.semcdb.2019.05.001_bib0305","doi-asserted-by":"crossref","first-page":"18226","DOI":"10.1073\/pnas.1317577110","article-title":"Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma","volume":"110","author":"Yuan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molonc.2015.08.003","article-title":"Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells","volume":"10","author":"Baenke","year":"2016","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.semcdb.2019.05.001_bib0315","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/ced.13119","article-title":"Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism","volume":"42","author":"Chang","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0320","article-title":"PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers","author":"Gentric","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus","volume":"22","author":"Canto","year":"2015","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.semcdb.2019.05.001_bib0330","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev."},{"issue":"6771","key":"10.1016\/j.semcdb.2019.05.001_bib0335","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","article-title":"Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase","volume":"403","author":"Imai","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0340","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"issue":"12","key":"10.1016\/j.semcdb.2019.05.001_bib0345","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.bbapap.2016.06.014","article-title":"NAD(+) metabolism: bioenergetics, signaling and manipulation for therapy","volume":"1864","author":"Yang","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0350","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2016.10.027","article-title":"NAD(+) salvage pathway in cancer metabolism and therapy","volume":"114","author":"Kennedy","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0355","article-title":"Regulation of cancer and cancer-related genes via NAD","author":"Sharif","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0360","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2014.16","article-title":"Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53\/NAD(H)-dependent and (ii) p53-independent pathways","volume":"3","author":"Allison","year":"2014","journal-title":"Oncogenesis"},{"issue":"6","key":"10.1016\/j.semcdb.2019.05.001_bib0365","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nrc.2015.19","article-title":"Metabolism: totally addicted to NAD(.)","volume":"16","author":"Shipman","year":"2016","journal-title":"Nat. Rev."},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0375","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2012.06.005","article-title":"The dynamic regulation of NAD metabolism in mitochondria","volume":"23","author":"Stein","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"6292","key":"10.1016\/j.semcdb.2019.05.001_bib0380","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.aad5168","article-title":"Biosensor reveals multiple sources for mitochondrial NAD(+)","volume":"352","author":"Cambronne","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0385","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.33246","article-title":"Nicotinamide adenine dinucleotide is transported into mammalian mitochondria","volume":"7","author":"Davila","year":"2018","journal-title":"Elife"},{"issue":"24","key":"10.1016\/j.semcdb.2019.05.001_bib0390","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M110.213298","article-title":"Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation","volume":"286","author":"Nikiforov","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.semcdb.2019.05.001_bib0395","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1111\/febs.12433","article-title":"Diversification of NAD biological role : the importance of location","volume":"280","author":"Di Stefano","year":"2013","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.semcdb.2019.05.001_bib0400","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.bbapap.2009.10.022","article-title":"SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions","volume":"1804","author":"Zhang","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tem.2013.12.001","article-title":"SIRT1 and other sirtuins in metabolism","volume":"25","author":"Chang","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"33","key":"10.1016\/j.semcdb.2019.05.001_bib0410","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1038\/onc.2010.206","article-title":"Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility","volume":"29","author":"Jeninga","year":"2010","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.semcdb.2019.05.001_bib0415","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.micinf.2012.05.011","article-title":"Extracellular NAD(+): a danger signal hindering regulatory T cells","volume":"14","author":"Adriouch","year":"2012","journal-title":"Microbes Infect. \/ Institut Pasteur"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0420","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mce.2016.11.003","article-title":"NAD and the aging process: role in life, death and everything in between","volume":"455","author":"Chini","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0425","doi-asserted-by":"crossref","DOI":"10.1111\/febs.13050","article-title":"Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD biosynthetic machinery in mammalian cells","author":"Zamporlini","year":"2014","journal-title":"FEBS J."},{"issue":"13","key":"10.1016\/j.semcdb.2019.05.001_bib0430","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2174\/092986711795590101","article-title":"NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism","volume":"18","author":"Burgos","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0435","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L","article-title":"Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis","volume":"32","author":"Rongvaux","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.semcdb.2019.05.001_bib0440","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/bies.10297","article-title":"Reconstructing eukaryotic NAD metabolism","volume":"25","author":"Rongvaux","year":"2003","journal-title":"Bioessays"},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0445","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","article-title":"Nampt\/PBEF\/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme","volume":"6","author":"Revollo","year":"2007","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/0008-5472.CAN-09-2465","article-title":"The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer","volume":"70","author":"Galli","year":"2010","journal-title":"Cancer Res."},{"issue":"37","key":"10.1016\/j.semcdb.2019.05.001_bib0455","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.2174\/138161212803582531","article-title":"Nampt\/Visfatin\/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors","volume":"18","author":"Jieyu","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"11-12","key":"10.1016\/j.semcdb.2019.05.001_bib0460","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601913507576","article-title":"Nicotinamide phosphoribosyltransferase in malignancy: a review","volume":"4","author":"Shackelford","year":"2013","journal-title":"Genes Cancer"},{"issue":"51","key":"10.1016\/j.semcdb.2019.05.001_bib0465","doi-asserted-by":"crossref","first-page":"E8247","DOI":"10.1073\/pnas.1610921114","article-title":"An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma","volume":"113","author":"Gujar","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0470","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1078-0432.CCR-17-2575","article-title":"NAMPT is a potent oncogene in Colon Cancer progression that modulates Cancer stem cell properties and resistance to therapy through Sirt1 and PARP","volume":"24","author":"Lucena-Cacace","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"59","key":"10.1016\/j.semcdb.2019.05.001_bib0475","doi-asserted-by":"crossref","first-page":"99514","DOI":"10.18632\/oncotarget.20577","article-title":"NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis","volume":"8","author":"Lucena-Cacace","year":"2017","journal-title":"Oncotarget"},{"issue":"49","key":"10.1016\/j.semcdb.2019.05.001_bib0480","doi-asserted-by":"crossref","first-page":"34189","DOI":"10.1074\/jbc.M114.594721","article-title":"Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity","volume":"289","author":"Soncini","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.semcdb.2019.05.001_bib0485","first-page":"7231","article-title":"FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0490","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fonc.2018.00622","article-title":"NAD metabolism in Cancer therapeutics","volume":"8","author":"Yaku","year":"2018","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0495","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1074\/jbc.M112.394510","article-title":"Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications","volume":"288","author":"Tan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.semcdb.2019.05.001_bib0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114019","article-title":"Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells","volume":"9","author":"Tolstikov","year":"2014","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.semcdb.2019.05.001_bib0505","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1074\/jbc.M114.632141","article-title":"Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells","volume":"290","author":"Tan","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0510","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx198","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-Mutated metastatic melanoma","volume":"110","author":"Audrito","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0515","article-title":"IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies","author":"Bergaggio","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0520","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1038\/srep13135","article-title":"Unique toll-like receptor 4 activation by NAMPT\/PBEF induces NFkappaB signaling and inflammatory lung injury","volume":"5","author":"Camp","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0525","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2017.tb00757.x","article-title":"Regulation and function of extracellular nicotinamide Phosphoribosyltransferase\/Visfatin","volume":"7","author":"Carbone","year":"2017","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0530","first-page":"1431","article-title":"Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor","volume":"14","author":"Samal","year":"1994","journal-title":"Mol. Cell. Biol."},{"issue":"5708","key":"10.1016\/j.semcdb.2019.05.001_bib0535","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1126\/science.1106933","article-title":"Medicine. Visfatin: a new adipokine","volume":"307","author":"Hug","year":"2005","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.semcdb.2019.05.001_bib0540","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/bph.13505","article-title":"Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine","volume":"173","author":"Grolla","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0545","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.178.3.1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties","volume":"178","author":"Moschen","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0550","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.bbamcr.2008.01.004","article-title":"Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells","volume":"1783","author":"Kim","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0555","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cvr\/cvm111","article-title":"Visfatin induces human endothelial VEGF and MMP-2\/9 production via MAPK and PI3K\/Akt signalling pathways: novel insights into visfatin-induced angiogenesis","volume":"78","author":"Adya","year":"2008","journal-title":"Cardiovasc. Res."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0560","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbamcr.2009.09.006","article-title":"Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis","volume":"1793","author":"Kim","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0565","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10059-010-0124-x","article-title":"Visfatin stimulates proliferation of MCF-7 human breast cancer cells","volume":"30","author":"Kim","year":"2010","journal-title":"Mol. Cells"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0570","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2017.05.002","article-title":"Metabolic regulation of suppressive myeloid cells in cancer","volume":"35","author":"Sica","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0575","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0580","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-18-1544","article-title":"Nicotinamide Phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells","author":"Travelli","year":"2019","journal-title":"Cancer Res."},{"issue":"40","key":"10.1016\/j.semcdb.2019.05.001_bib0585","doi-asserted-by":"crossref","first-page":"27344","DOI":"10.1074\/jbc.M109.002519","article-title":"Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism","volume":"284","author":"Liu","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.semcdb.2019.05.001_bib0590","doi-asserted-by":"crossref","first-page":"34833","DOI":"10.1074\/jbc.M805866200","article-title":"Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6\/STAT3 signaling mechanism","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.semcdb.2019.05.001_bib0595","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00125-009-1509-2","article-title":"Extracellular PBEF\/NAMPT\/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity","volume":"52","author":"Romacho","year":"2009","journal-title":"Diabetologia"},{"issue":"7255","key":"10.1016\/j.semcdb.2019.05.001_bib0600","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08197","article-title":"Recent progress in the biology and physiology of sirtuins","volume":"460","author":"Finkel","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0605","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/npjsba.2016.18","article-title":"The NAD World 2.0: the importance of the inter-tissue communication mediated by NAMPT\/NAD(+)\/SIRT1 in mammalian aging and longevity control","volume":"2","author":"Imai","year":"2016","journal-title":"NPJ Syst. Biol. Appl."},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0610","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10239.x","article-title":"Noninvasive genomic detection of melanoma","volume":"164","author":"Wachsman","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0615","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/pcmr.12037","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions","volume":"26","author":"Maldi","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbrc.2017.09.071","article-title":"The NAMPT\/E2F2\/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells","volume":"493","author":"Zhao","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.semcdb.2019.05.001_bib0625","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/pcmr.12420","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT\/PBEF\/visfatin) is a tumoural cytokine released from melanoma","volume":"28","author":"Grolla","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"issue":"27","key":"10.1016\/j.semcdb.2019.05.001_bib0630","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.18632\/oncotarget.24871","article-title":"Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF\u2013mutated metastatic melanoma","volume":"9","author":"Audrito","year":"2018","journal-title":"Oncotarget"},{"issue":"5-6","key":"10.1016\/j.semcdb.2019.05.001_bib0635","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1101\/gad.305854.117","article-title":"Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype","volume":"32","author":"Ohanna","year":"2018","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0640","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ijc.31808","article-title":"NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils","volume":"144","author":"Pylaeva","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"21","key":"10.1016\/j.semcdb.2019.05.001_bib0645","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcdb.2019.05.001_bib0650","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","article-title":"Anticancer agent CHS-828 inhibits cellular synthesis of NAD","volume":"367","author":"Olesen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcdb.2019.05.001_bib0655","doi-asserted-by":"crossref","DOI":"10.1021\/jm4001049","article-title":"Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors","author":"Galli","year":"2013","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0660","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bmcl.2014.12.026","article-title":"Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility","volume":"25","author":"Zak","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.semcdb.2019.05.001_bib0665","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney Cancer growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.semcdb.2019.05.001_bib0670","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1021\/acs.jmedchem.6b01392","article-title":"Identification of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors endowed with Antiproliferative and antiinflammatory activity","volume":"60","author":"Travelli","year":"2017","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.semcdb.2019.05.001_bib0675","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/1389450111314060003","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience","volume":"14","author":"Montecucco","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.semcdb.2019.05.001_bib0680","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2016.1190649","article-title":"Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities","volume":"16","author":"Chen","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"12","key":"10.1016\/j.semcdb.2019.05.001_bib0685","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1593\/neo.131718","article-title":"Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models","volume":"15","author":"O\u2019Brien","year":"2013","journal-title":"Neoplasia"},{"issue":"4-5","key":"10.1016\/j.semcdb.2019.05.001_bib0690","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0463.2011.02733.x","article-title":"Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas","volume":"119","author":"Olesen","year":"2011","journal-title":"APMIS"},{"issue":"14","key":"10.1016\/j.semcdb.2019.05.001_bib0695","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-16-3079","article-title":"Nicotinic acid phosphoribosyltransferase regulates Cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair","volume":"77","author":"Piacente","year":"2017","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.semcdb.2019.05.001_bib0700","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1158\/1078-0432.CCR-13-1186","article-title":"Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors","volume":"19","author":"Shames","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcdb.2019.05.001_bib0705","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.18632\/oncotarget.6538","article-title":"Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors","volume":"7","author":"Duarte-Pereira","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcdb.2019.05.001_bib0710","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbrc.2017.07.143","article-title":"Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation","volume":"491","author":"Guo","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.semcdb.2019.05.001_bib0715","article-title":"Structural basis for resistance to diverse classes of NAMPT inhibitors","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.semcdb.2019.05.001_bib0720","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.18632\/oncotarget.24731","article-title":"Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment","volume":"9","author":"Ogino","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcdb.2019.05.001_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-018-0174-7","article-title":"Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA","volume":"6","author":"Thongon","year":"2018","journal-title":"Cancer Metab."},{"issue":"1","key":"10.1016\/j.semcdb.2019.05.001_bib0730","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1165\/rcmb.2017-0155OC","article-title":"Novel mechanism for nicotinamide phosphoribosyltransferase inhibition of TNF-alpha-mediated apoptosis in human lung endothelial cells","volume":"59","author":"Oita","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."}],"container-title":["Seminars in Cell &amp; Developmental Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952118302039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952118302039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:56:39Z","timestamp":1761065799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1084952118302039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":146,"alternative-id":["S1084952118302039"],"URL":"https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.001","relation":{},"ISSN":["1084-9521"],"issn-type":[{"value":"1084-9521","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cell & Developmental Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}